Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical ...

Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $20.94 which represents a decrease of $-0.55 or -2.56% from the prior close of $21.49. The stock opened at $21.27 and ...

Samsung Bioepis collaborates with Teva to launch Epysylli in U.S. market Samsung Bioepis and Teva join forces to introduce a ...

Argus has recently raised Teva Pharmaceutical Industries Ltd (TEVA) stock to Buy rating, as announced on July 10, 2024, according to Finviz. Earlier, on March 8, 2024, JP Morgan had raised the stock ...

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd ...

Pharmaceutical Industries announced that the companies have entered into a license, development and commercialization agreement for EPYSQLI, Samsung Bioepis’ biosimilar to Soliris in the United States ...

TEV-56278 is under clinical development by Teva Pharmaceutical Industries and currently in Phase I for Solid Tumor.

In its survey of the Internet sector, Cantor Fitzgerald selected Wix, led by CEO Avishai Abrahami, as a top pick, along with ...

BofA keeps a Buy rating on Catalyst Pharmaceuticals (CPRX) with a $30 price target following the announcement of a Firdapse patent settlement ...

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH),atypical hemolytic uremic syndrome (aHUS)andgeneralized myasthenia gravis (gMG)in the U ...

Teva Pharmaceutical Industries Ltd is a global leader in the pharmaceutical industry, specializing in the development, manufacture, and distribution of generic and specialty medicines, as well as ...

Global Spinal Cord Injury Therapeutics Market is estimated to valued US$ 7.4 billion in 2023 & expected to exhibit CAGR of 5.4% during forecast period 2023-2030 Mr. Shah Coherent Market Insights Pvt.